Targeted but not trouble-free: efalizumab and PML
ES Molloy, LH Calabrese - Nature reviews Rheumatology, 2009 - nature.com
ES Molloy, LH Calabrese
Nature reviews Rheumatology, 2009•nature.comIn April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after
reports emerged of an association between long-term therapy and the development of
progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for
greater awareness and research into the screening, diagnosis and treatment of this
potentially fatal disease in patients undergoing immunosuppressive therapy for chronic
inflammatory disorders.
reports emerged of an association between long-term therapy and the development of
progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for
greater awareness and research into the screening, diagnosis and treatment of this
potentially fatal disease in patients undergoing immunosuppressive therapy for chronic
inflammatory disorders.
In April 2009, efalizumab was withdrawn from the market for the treatment of psoriasis after reports emerged of an association between long-term therapy and the development of progressive multifocal leukoencephalopathy (PML). This event highlights an urgent need for greater awareness and research into the screening, diagnosis and treatment of this potentially fatal disease in patients undergoing immunosuppressive therapy for chronic inflammatory disorders.
nature.com